SAN FRANCISCO, CAAmong patients with severe aortic stenosis at low surgical risk, TAVR is associated with improved disease-specific health status over SAVR at not only 1 month but also 6 and 12 months, according to a PARTNER 3 substudy.
Despite the fact that patients werent overly symptomatic at baseline, these patients still saw a large improvement in quality of life, Suzanne J. Baron, MD (Lahey Hospital and Medical Center, Burlington, MA), told TCTMD. So even in the low-risk population, there is a huge value from a patient-reported outcomes standpoint with [TAVR]. Baron presented the findings today in a late-breaking clinical trial session here at TCT 2019.
Another take-home message from this analysis, which was simultaneously published in the Journal of the American College of Cardiology, is that the small but sustained improvement observed with TAVR over SAVR through 1 year represents a significant benefit for a subset of patients, Baron said, noting that these are likely patients who are more symptomatic at baselinewith NYHA class III or IV symptoms.
Its information that a clinician can use for patients in whom you are trying to decide [if TAVR or SAVR] is the right way to go, she explained. In some cases it's very clear. If a patient has a huge calcium shelf, then surgery is going to be the better way for them, fine. But for patients where it's really borderline, the clinician takes a look and says the patient is . . . a little more frail, a little more symptomatic, maybe that is the patient that going to do better with TAVR from a health status outcomes standpoint.
A lot of these patients may still be working and caring for grandkids or elderly parents. It becomes a lot more of an issue. Suzanne J. Baron
To TCTMD, Philippe Gnreux, MD (Morristown Medical Center, NJ), who was a panelist in press conference yesterday, said these results will be helpful for physician conversations with patients. [But] I can tell you that the discussion is very brief because patients are asking for [TAVR]. Its not a very big sell to not have a chest opened in terms of quality of life. We see a lot of healthy patients, 60 years old, that want to go back to work next week. That's what is driving the discussion, he explained.
Until now, much of the focus for low-risk TAVR has been on hard outcomes like death, MI, stroke, and rehospitalization, Baron added.
However, patient-reported outcomes are incredibly important, too, she said. I've got plenty of patients who say, I don't mind if I die, but please, I do not want a stroke because I do not want to live like that. . . . A lot of these patients want to get back to what they're doingthey want to be able to interact with their familiesand in the low-risk populations it's even more important. A lot of these patients may still be working and caring for grandkids or elderly parents. It becomes a lot more of an issue.
Large Benefit in Small Proportion
As reported by TCTMD, the PARTNER 3 trial demonstrated that TAVR with the balloon-expandable Sapien 3 transcatheter heart valve (Edwards Lifesciences) was better than surgery for the prevention of death, stroke, and rehospitalization at 1 year. PARTNER 3 included 1,000 patients with an STS Predicted Risk of Mortality of less than 4% (mean score 1.9%) treated at 71 centers. The average age of those treated was 73.4 years, and nearly 70% of patients were men.
In this substudy, Baron and colleagues used the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score (ranging from 0 to 100) to assess health status outcomes through 1 year in both study groups. The mean baseline KCCQ overall summary score was 70 for both TAVR and SAVR patients, which corresponds to NYHA class II symptoms.
As expected, TAVR patients demonstrated substantially improved health status at 1 month. Baron reported that, unlike in earlier studies, the benefit of TAVR over surgery persisted through 6 (2.6-point difference; P = 0.002) and 12 months (1.8-point difference; P = 0.03), although the magnitude was smaller. at 1 year, both groups had experienced an increase of about 19 points from baseline, which is consistent with a large clinical improvement.
The findings were confirmed on several KCCQ subscales, but no difference was observed in health status outcomes at 1 year on generic measures like the SF-36 physical and mental summary scores. Baron said this was likely reflective of the fact that as a disease specific measure, the KCCQ is much more sensitive at detecting meaningful differences in this population.
When change in health status was analyzed as an ordinal variable with death as the worst outcome and a large clinical improvement defined as a greater than 20-point increase in the KCCQ overall summary score, TAVR demonstrated a significant benefit compared with surgery at all time points.
To further explore the mechanism of the benefit observed in this study, the researchers generated cumulative distribution curves to determine the proportion of patients achieving various changes in KCCQ overall summary score at 1 year. There was a clear separation of the curves with more TAVR patients experiencing a change of 20 points or greater when compared with surgery, Baron reported, adding that the difference in late health status between the two groups was driven by the 5.2% absolute risk difference in the proportion of patients who experienced a large clinical improvement.
Prespecified subgroup analyses showed no difference in KCCQ overall summary score for TAVR vs SAVR by age, gender, STS risk score, ejection fraction, and A-fib, but there was a significant interaction between baseline NYHA class and treatment effect with patients who had NYHA class III or IV symptoms at baseline deriving greater benefit from TAVR than those categorized as NYHA class I or II (P = 0.020 for interaction).
Additionally, on exploratory analyses to determine whether differences in periprocedural complications between the groups could explain the observed health status benefit, Baron and colleagues found a 1.8-point adjusted difference in KCCQ overall summary score between TAVR and SAVR at 1 year. This treatment effect was mildly attenuated when 30-day complications were added to the model, but a 1.3-point difference in the KCCQ overall summary score remained in favor of TAVR. It suggests that periprocedural complications play a partial role but not a full role in the sustained health benefits, Baron said.
Frailty, Complications May Matter
In a media briefing, Suzanne Arnold, MD (Saint Lukes Mid America Heart Institute, Kansas City, MO), noted two really remarkable aspects about the substudy. The first is that the patients were not particularly symptomatic going into this and yet still had a nearly 20-point improvement post-TAVR, she said. [This] may speak to the aspect that KCCQ is very disease-specific and these patients don't really have a lot of other comorbidities that are going to potentially impact their health status.
Secondly, Arnold commented that while a two-point increase is not a large benefit per se, those cumulative response curves are really interesting because I think it highlights that small percentage of patients who seem to get a larger benefit. As to why this might be, whether there are particular subgroups or complications driving this benefit, Arnold said its unclear, but its possible that frailty might play a role.
Frail patients were not included in PARTNER 3, but was there any signal of prefrail patients that may not have a lot of comorbidities but may have some mobility deficit that might have impacted their ability to recover from the surgery? she asked.
Baron replied that some frailty measures were collected in the overall trial but no participants met the criteria for overall frailty. We did do a subgroup analysis on patients who had two or more markers of frailty versus those that had one or less, she said, noting that only 20 patients were included. We did see a significant signal that patients who were considered to have two or more frail measures were considered to do much better with TAVR. It does make you think that is there something about the NYHA class that a clinician takes a look at a patient and just from that eyeball test says this patient just doesn't look functionally great. . . . Maybe it's those patients who are going to do a little bit better with TAVR vs surgery with all other things being equal.
Juan Granada, MD (Cardiovascular Research Foundation, New York, NY), who moderated the media briefing, commented on the evolution of TAVR from inoperable to low-risk patients and the associated economic implications. What has been the evolution throughout the years in terms of the financial impact for hospitals and centers according to the risk of the patient? he asked, addressing the panel.
When you deal with very sick patients, they stay longer in the hospital, which costs more, Gnreux replied. Now, were dealing with less-sick patients, but we've become very efficient and [have] less complications. . . . The rate of rehospitalization is lower, so weve become much more cost-effective, and with all the new tools that are coming that may increase the cost of the procedure, we reduce the complications [further].
Baron added that no data are available yet on cost-effectiveness of low-risk TAVR, but we do know that when weve compared inoperables versus high-risk versus intermediate-risk, we've seen that the procedure becomes substantially more cost-effective even so that in the intermediate-risk population it was actually cost saving. A lot of this has been driven by decreasing rates of complications, but more importantly, decreasing length of stay in the hospital associated with TAVR.
The big message is the trend continues to be the same, Granada summarized. One of the things that I really think is going to be determined in the future is the impact of technological improvements and procedural experience on cost, because at the end of the day what is going to drive cost . . . is how many patients need to come back for reevaluation and paravalvular leak treatments. If the technology continues to improve and those signals start to disappear then it's going to really start to do even better, . . . but time will tell.
Baron told TCTMD that they will continue to follow these patients out to determine long-term outcomes. Durability is going to be the key both for hard outcomes, for how well the valve is functioning, and all patient reported outcomes, she said. I don't have a reason to think that this benefit wouldn't sustain past a year, because again people are recovered from the procedure, so if it's there at a year, I don't know why it wouldn't necessarily be there at 2 years, 3 years, and 4 years, assuming that there's no difference in health durability. But we're going to get those answers.
Note: Several co-authors are faculty members of the Cardiovascular Research Foundation, the publisher of TCTMD.
Read the rest here:
TAVR Improves Health Status Over Surgery in Low-Risk Patients at 1 Year: PARTNER 3 - TCTMD
- Best 30 Cardiology in Secaucus, NJ with Reviews - YP.com - April 12th, 2018 [April 12th, 2018]
- Cardiology | Weill Cornell Medicine - April 14th, 2018 [April 14th, 2018]
- Cardiology Conferences 2018 | Cardiology Meetings 2018 ... - April 26th, 2018 [April 26th, 2018]
- Dr. Anil Goel, MD - Birmingham, MI - Cardiology & Clinical ... - April 26th, 2018 [April 26th, 2018]
- Clinical Physiology (Cardiology) MSc/PGDip | Middlesex ... - May 15th, 2018 [May 15th, 2018]
- Cardiology Conferences 2018 | Upcoming Cardiology ... - May 16th, 2018 [May 16th, 2018]
- Clinical Cardiology Section | Cleveland Clinic - May 27th, 2018 [May 27th, 2018]
- Journal of Clinical and Experimental Cardiology - Open ... - June 6th, 2018 [June 6th, 2018]
- Cardiology Summit 2018 | Cardiology Conferences | Heart ... - June 23rd, 2018 [June 23rd, 2018]
- Cardiology Clinical and Research Faculty Members ... - June 26th, 2018 [June 26th, 2018]
- Cardiology Conferences 2018 | Cardiology Congress 2018 ... - June 26th, 2018 [June 26th, 2018]
- About Us - New Jersey Cardiology Associates - July 8th, 2018 [July 8th, 2018]
- About Us - Ventura Clinical Trials - August 16th, 2018 [August 16th, 2018]
- Clinical Cardiology Made Ridiculously Simple: Michael A ... - August 22nd, 2018 [August 22nd, 2018]
- Clinical Cardiology - American Society of Preventive Cardiology - October 2nd, 2018 [October 2nd, 2018]
- Heart Surgery Hospital in india | Cardiology Treatment ... - October 7th, 2018 [October 7th, 2018]
- Clinical Cardiology - American Society of Preventive ... - December 3rd, 2018 [December 3rd, 2018]
- Guideline Clinical App - American College of Cardiology - December 7th, 2018 [December 7th, 2018]
- Journal of Clinical and Experimental Cardiology- Open ... - December 12th, 2018 [December 12th, 2018]
- Clinical Cardiology - Baptist Health - December 30th, 2018 [December 30th, 2018]
- Cardiology at Cancun: Topics in Clinical Cardiology - February 5th, 2019 [February 5th, 2019]
- Department of Cardiovascular Medicine, KU School of Medicine - March 10th, 2019 [March 10th, 2019]
- Towards Health Equality: Improving the Management of Cardiovascular Diseases in Women - International Atomic Energy Agency - September 21st, 2019 [September 21st, 2019]
- Lifetime Risk of PAD Varies by Race, but All Are Vulnerable to Traditional Risk Factors - TCTMD - September 21st, 2019 [September 21st, 2019]
- DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF - TCTMD - September 21st, 2019 [September 21st, 2019]
- Combining Nature and Technology, Luye Medical and Cleveland Clinic Join to Build a Future Hospital in Shanghai - Yahoo Finance - September 21st, 2019 [September 21st, 2019]
- Will Renal Denervation for Hypertension Rise Again? - Medscape - September 21st, 2019 [September 21st, 2019]
- Obstructive Sleep Apnea, Sleep Symptoms, and their Association with Cardiovascular Disease - DocWire News - September 21st, 2019 [September 21st, 2019]
- CNE expands pulmonary, sleep services with Brigham & Women's physicians - Warwick Beacon - September 21st, 2019 [September 21st, 2019]
- What I Am Most Looking Forward to at TCT 2019 - TCTMD - September 21st, 2019 [September 21st, 2019]
- Serelaxin Not Linked to CV Mortality Reduction in Patients Hospitalized for Acute HF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Sacubitril-Valsartan Not Linked to Lower Hospitalization Risk, CV Death in HFpEF - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- FDA clears multiuse angiography systems from Siemens Healthineers - DOTmed HealthCare Business News - September 21st, 2019 [September 21st, 2019]
- Balloon Pulmonary Angioplasty Effective for Chronic Thromboembolic PH - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- RWJBarnabas Health, St. Luke's University Health launch clinical affiliation - FierceHealthcare - September 21st, 2019 [September 21st, 2019]
- Bilirubin: A Novel Indicator of Infective Endocarditis Adverse Outcomes - The Cardiology Advisor - September 21st, 2019 [September 21st, 2019]
- Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS - TCTMD - September 21st, 2019 [September 21st, 2019]
- Community-based Care Model Reduces CVD Risk - Managed Healthcare Executive - September 21st, 2019 [September 21st, 2019]
- American College of Cardiology Steps Up: Equal Pay, Opportunities for All - TCTMD - September 21st, 2019 [September 21st, 2019]
- FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form - AJMC.com Managed Markets Network - September 21st, 2019 [September 21st, 2019]
- A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred - Medscape - September 21st, 2019 [September 21st, 2019]
- Seeking Synergy: Bringing Cardiology into Your Enterprise Imaging Strategy - Health Imaging - September 21st, 2019 [September 21st, 2019]
- TCT 2019 Day Two: Transcatheter Valves, New and Old - TCTMD - September 30th, 2019 [September 30th, 2019]
- Transcatheter Options Best for Tricuspid Regurgitation in Matched Registry Analysis - TCTMD - September 30th, 2019 [September 30th, 2019]
- Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival - Diagnostic and Interventional Cardiology - September 30th, 2019 [September 30th, 2019]
- Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy... - September 30th, 2019 [September 30th, 2019]
- Off Script: The New Gatekeepers of Procedural Education - TCTMD - September 30th, 2019 [September 30th, 2019]
- Study Shows Safety and Efficacy of Near Infrared Spectroscopy (NIRS) Imaging to Identify Patients and Plaques at an Increased Risk for MACE - BioSpace - September 30th, 2019 [September 30th, 2019]
- The Heart of the Matter: Cardiovascular Fitness in Horses - United States Eventing Association - September 30th, 2019 [September 30th, 2019]
- Google parent Alphabet hires former FDA head Robert Califf to lead health strategy and policy - FierceHealthcare - September 30th, 2019 [September 30th, 2019]
- Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- AUGUSTUS: Best Benefit With Apixaban, P2Y12 Inhibitor Dual Therapy - Medscape - September 30th, 2019 [September 30th, 2019]
- New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis - Newswise - September 30th, 2019 [September 30th, 2019]
- Dapagliflozin Improves Heart Failure-Related Health Status in HFrEF - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Remote Ischemic Conditioning Did Not Improve 12 Month Clinical Outcomes After STEMI - The Cardiology Advisor - September 30th, 2019 [September 30th, 2019]
- Insights from the European Society of Cardiology congress | Speaking of Medicine - PLoS Blogs - September 30th, 2019 [September 30th, 2019]
- Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- AZ's Farxiga gets heart failure prevention okay from FDA - PMLiVE - October 22nd, 2019 [October 22nd, 2019]
- Bayer Announces Recipients of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards at CHEST Annual Meeting 2019 - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- The Epidemic Of The Metabolic Syndrome Among The Palestinians In The G | DMSO - Dove Medical Press - October 22nd, 2019 [October 22nd, 2019]
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis - PRNewswire - October 22nd, 2019 [October 22nd, 2019]
- Even With Same Diagnosis, Women Get Half the Heart Attack Treatments as Men - AJMC.com Managed Markets Network - October 22nd, 2019 [October 22nd, 2019]
- Eva Dickerman, Andrew Weil - The New York Times - October 22nd, 2019 [October 22nd, 2019]
- EHR vendor Veradigm and partners creating new shared data tools for researchers - Healthcare IT News - October 22nd, 2019 [October 22nd, 2019]
- Evolocumab Well-tolerated as Add-on for Hypercholesterolemia Therapy - DocWire News - October 22nd, 2019 [October 22nd, 2019]
- Deborah Heart and Lung Center announces affiliation with Cleveland Clinic Heart & Vascular Institute - Health Essentials from Cleveland Clinic - October 22nd, 2019 [October 22nd, 2019]
- New Registry to Provide Insight into STEMI Occurrence, Treatment in North India | - Diagnostic and Interventional Cardiology - October 22nd, 2019 [October 22nd, 2019]
- Finding Your Best Fit in Cardiology - TCTMD - October 22nd, 2019 [October 22nd, 2019]
- Cardiology team expands to meet community need - The Union of Grass Valley - October 22nd, 2019 [October 22nd, 2019]
- Deaths After Ablation of Atrial Fibrillation 'Concerning' in Real-World Analysis - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cutler Family gifts $15 million to University Hospitals to transform mens health care - Newswise - November 1st, 2019 [November 1st, 2019]
- Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD - TCTMD - November 1st, 2019 [November 1st, 2019]
- Caregiving and the Soul of Medicine - Medscape - November 1st, 2019 [November 1st, 2019]
- STEMI Mortality Unaffected by Weekend, Weeknight, or Holiday Admission in France - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical publishes positive results from the AMBULATE pivotal study Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Gaps in Access to TAVR and SAVR: 'Something Needs to Be Done' - TCTMD - November 1st, 2019 [November 1st, 2019]
- Cardiva Medical Announces Publication of Data From the AMBULATE Pivotal Study in the Journal of the American College of Cardiology: Clinical... - November 1st, 2019 [November 1st, 2019]
- Raymond James 4 Analyst Favorite Health Care Picks With Huge Upside Potential - 24/7 Wall St. - November 7th, 2019 [November 7th, 2019]
- Global Computed Tomography (CT) Scanners Devices and Equipment Market Report 2020: Major Players are GE Healthcare, Koninklijke Philips, Hitachi,... - November 7th, 2019 [November 7th, 2019]
- Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD - TCTMD - November 7th, 2019 [November 7th, 2019]